SCHEMBL3520873

SCHEMBL3520873

CCOC(=O)CNC(=O)c1c(O)c(-c2cccc(F)c2)cc2nc(-c3ccc(F)c(F)c3)cnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.40
KDM4E B2RXH2 2/20 0.40
WNT3A P56704 1/20 0.36
DHODH Q02127 1/20 0.36
EGLN1 Q9GZT9 2/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
LMNA P02545 1/20 0.35
F2 P00734 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PPID Q08752 1/20 0.34
CSNK1D P48730 1/20 0.34
TP53 P04637 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519403 0.94 EGLN3 (0.40) EGLN3KDM4EEGLN1LMNAF2
SCHEMBL3756274 0.88 EGLN3 (0.52) EGLN3WNT3AEGLN1ATRVEGFA
SCHEMBL3518979 0.87 EGLN3 (0.36) EGLN3KDM4ELMNAHSD17B10MEN1
SCHEMBL3534707 0.86 EGLN3 (0.41) EGLN3KDM4EEGLN1TRPM8LMNA
SCHEMBL3519757 0.86 EGLN3 (0.38) EGLN3KDM4ELMNAF2HSD17B10
SCHEMBL3519311 0.85 GAA (0.36) EGLN3KDM4EEGLN1LMNAF2
SCHEMBL3526639 0.84 EGLN3 (0.36) EGLN3KDM4EWNT3ALMNAHSD17B10
SCHEMBL3518821 0.84 EGLN3 (0.49) EGLN3KDM4ELMNAHSD17B10PPID
SCHEMBL3521148 0.83 EGLN3 (0.46) EGLN3KDM4EWNT3ADHODHEGLN1
SCHEMBL3519260 0.82 EGLN3 (0.53) EGLN3EGLN1NPC1RAB9AVEGFA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885KDM4E 176/4885WNT3A 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.